Loading the Knowledge Navigator, please wait.

We are transforming the patient experience in mental health care. We think differently about mental health and are acting urgently to deliver innovation that will enable people to live happier and healthier lives.​

Click below to find out more

The mental health crisis

We are leaders in innovation

Latest results

There are too many people who are suffering with mental health challenges like depression, and who aren’t helped by existing therapies.

Click below to find out more

COMP360 psilocybin therapy has the potential to help those who are suffering and don't have many options.

Click below to find out more

Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support​​

Click below to find out more

Primary endpoint – change from baseline in MADRS total score

Key secondary endpoint - MADRS responders

Key secondary endpoint - MADRS remitters

Safety – treatment emergent adverse events (TEAEs) overview​

Study design and endpoints​

MADRS sustained responders at week 12​

Please rotate your device landscape to view this website